This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Long-term Follow-up of Subfoveal Neovascular AMD

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2012 by Christopher Kiss, Medical University of Vienna.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Christopher Kiss, Medical University of Vienna Identifier:
First received: April 10, 2012
Last updated: May 25, 2012
Last verified: May 2012
Treatment naive patients with subfoveal nAMD initially treated monthly with intravitreal anti-VEGF and subsequently PRN, will be included in this study. Patients will be investigated for the first 2 years monthly and subsequently according to disease activity but at least every two months. Patients will be examined with 4m BCVA ETDRS distance visual acuity, reading acuity measured by Radner-Reading-Charts, contrast sensitivity by Pelli-Robson score, microperimetry and HD-OCT.

Exudative Age-related Macular Degeneration

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Christopher Kiss, Medical University of Vienna:

Primary Outcome Measures:
  • Long-term visual function performance [ Time Frame: four years ]

Secondary Outcome Measures:
  • change of morphological alterations assessed by SD-OCT [ Time Frame: four years ]

Estimated Enrollment: 70
Study Start Date: September 2011

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients suffering on treatment naive subfoveal neovascular age-related macular degeneration

Inclusion Criteria:

  • treatment naive subfoveal AMD, written informed consent, able to read

Exclusion Criteria:

  • choroidal neovascularisation due to other ocular diseases, mature cataract
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01608113

Department of Ophthalmology Medical University of Vienna Recruiting
Vienna, Austria, 1190
Contact: Jasmin Mittermüller    00431404004847      
Contact: Germana Armberger    00431404004847      
Sub-Investigator: Florian Sulzbacher, MD         
Sub-Investigator: Marion Munk, MD         
Sub-Investigator: Philipp Roberts, MD         
Sub-Investigator: Katharina Eibenberger, MD         
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Christopher G Kiss, MD Medical University Vienna
  More Information

Responsible Party: Christopher Kiss, Head of Vienna Study Center, Medical University of Vienna Identifier: NCT01608113     History of Changes
Other Study ID Numbers: EK 802/2011
Study First Received: April 10, 2012
Last Updated: May 25, 2012

Keywords provided by Christopher Kiss, Medical University of Vienna:
neovascular AMD
Optical coherence tomography
reading acuity
contrast sensitivity

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases processed this record on August 22, 2017